In a report released today, Andrew Fein from H.C. Wainwright maintained a Buy rating on Wave Life Sciences (WVE – Research Report), with ...

Wave Life Sciences' stock soars on positive initial data showing the first-ever therapeutic RNA editing in humans in the ...

US RNA medicines biotech Wave Life Sciences yesterday announced positive proof-of-mechanism data from the ongoing Phase ...

Wave Life Sciences (WVE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings ...

Wave Life Sciences reports that it has successfully carried out RNA editing in two patients with alpha-1 antitrypsin ...

Mizuho Securities analyst Salim Syed has maintained their bullish stance on WVE stock, giving a Buy rating today. Salim Syed’s rating is ...

Wave claims this is the first clinical data with a therapeutic RNA-editing drug in humans, an achievement that boosted its ...